Showing 116 of 116on this page. Filters & sort apply to loaded results; URL updates for sharing.116 of 116 on this page
SPR720 (Fobrepodacin) | Working Group for New TB Drugs
PPT - SPR720 PowerPoint Presentation, free download - ID:4010237
Efficacy of SPR720 in murine models of non-tuberculous mycobacterial ...
Spero starts Phase l trial of SPR720 for NTM infections
SPR720 disodium – Xcess Biosciences
Spero Therapeutics Announces Publication of SPR720 Phase 1
Spero Therapeutics announces Initiation of SPR720 Phase 1 Clinical Trial
Spero Therapeutics Provides Update on SPR720 Phase 2a
Spero Therapeutics receives ODD for its oral drug SPR720 from the FDA
Fobrepodacin (SPR720) | Antibacterial Agent | MedChemExpress
Full article: Nontuberculous mycobacterial pulmonary disease and the ...
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal ...
Slide 1
Slide 23
Slide 29
Slide 36
Slide 30
Slide 33
Slide 24
Slide 28
(PDF) First-in-Human Evaluation of the Safety, Tolerability, and ...
Slide 17
Slide 20
Slide 27
Slide 31
Slide 19
Slide 25
Slide 35
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued ...
First-in-Human Evaluation of the Safety, Tolerability, and ...
WEBLEY & SCOTT – WEBLEY JUNIOR, AIR PISTOL Part No # J12, WEBLEY JUNIOR ...
Spero Therapeutics | Developing MDR Bacterial Infection Treatments
Slide 38
Infectious Diseases | University of Illinois Chicago
Slide 22
Spero Therapeutics: R&D Day on Non-Tuberculous Mycobacteria Pulmonary ...
The drug developers fighting the antibiotic resistance problem ...
Slide 16
Antibiotic Pipeline for Gram-Negative Bacteria | Spero Therapeutics
Intrapulmonary pharmacokinetics of SPR719 following oral administration ...
Slide 32
Slide 15
M. avium Complex Pulmonary Infections: Therapeutic Obstacles and ...
Spero Therapeutics (SPRO) Stock Price & Overview
Slide 37
Exploring the 5-Substituted 2-Aminobenzothiazole-Based DNA Gyrase B ...
(PDF) 1637. SPR720, A Novel Benzamidazole Gyrase Inhibitor ...
Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead
Slide 26
Slide 34
Geometric mean plasma SPR719 concentration-time curves following single ...
Slide 39
Spero Therapeutics: Multi-Asset Pipeline Could Outpace Tebipenem HBr ...
Pharmacokinetic profile and efficacy of TPP8 in mice. (A) Plasma ...
Structure-based design, synthesis, computational screening and ...
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug ...
Slide 21
New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum ...
具有抗结核活性的嘧啶衍生物,European Journal of Medicinal Chemistry - X-MOL
Spero Therapeutics (SPRO) – 2H2019 Readouts | JaguarAnalytics
Slide 6
Antibacterial Prodrugs to Overcome Bacterial Antimicrobial Resistance
Inhibitors targeting DNA replication and protein synthesis | Download ...
Hydrazineyl-linked imidazole[1,2-a]pyrimidine-thiazole hybrids: design ...
Fobrepodacin | TargetMol
NTM Info & Research - Spero Therapeutics, Inc., a multi-asset clinical ...
Frontiers | Treatment for non-tuberculous mycobacteria: challenges and ...
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable ...
Spero’s stock slides after antibiotic flops in Phase II trial
Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and ...
Mintz Represents Spero Therapeutics | Mintz
首个口服碳青霉烯类抗生素：GSK 和 Spero达成独家许可协议，共同开发Tebipenem HBr治疗成人复杂性尿路感染 - 知乎
Statistical analysis of food effect on the PK of SPR719 following ...
